Vir Biotechnology (NASDAQ:VIR) CFO Jason O’byrne Sells 2,089 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CFO Jason O’byrne sold 2,089 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $7.45, for a total transaction of $15,563.05. Following the sale, the chief financial officer owned 164,249 shares in the company, valued at approximately $1,223,655.05. This trade represents a 1.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Vir Biotechnology Trading Up 27.7%

Vir Biotechnology stock opened at $9.49 on Wednesday. The stock’s fifty day simple moving average is $6.80 and its 200-day simple moving average is $5.99. The firm has a market capitalization of $1.32 billion, a P/E ratio of -3.00 and a beta of 1.69. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $10.29.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 47.14%. The firm had revenue of $64.07 million for the quarter, compared to analyst estimates of $19.91 million. During the same period in the prior year, the firm earned ($0.76) earnings per share. The business’s quarterly revenue was up 417.8% compared to the same quarter last year. Sell-side analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on VIR. Barclays restated an “overweight” rating and issued a $30.00 price target on shares of Vir Biotechnology in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Vir Biotechnology in a research note on Tuesday, December 30th. Evercore reaffirmed an “outperform” rating and issued a $18.00 price target on shares of Vir Biotechnology in a report on Tuesday. Raymond James Financial raised shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price objective on the stock in a report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.88.

Hedge Funds Weigh In On Vir Biotechnology

A number of hedge funds have recently modified their holdings of the business. Corient Private Wealth LLC raised its position in Vir Biotechnology by 1.0% in the 4th quarter. Corient Private Wealth LLC now owns 262,211 shares of the company’s stock valued at $1,572,000 after purchasing an additional 2,515 shares during the last quarter. Virtus Investment Advisers LLC increased its stake in Vir Biotechnology by 82.4% in the fourth quarter. Virtus Investment Advisers LLC now owns 39,764 shares of the company’s stock valued at $240,000 after purchasing an additional 17,966 shares during the period. Tudor Investment Corp ET AL purchased a new stake in shares of Vir Biotechnology in the fourth quarter valued at about $414,000. Polymer Capital Management US LLC acquired a new stake in shares of Vir Biotechnology during the fourth quarter worth about $202,000. Finally, Quadrature Capital Ltd purchased a new position in shares of Vir Biotechnology during the fourth quarter worth about $300,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Vir Biotechnology News Summary

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration: Vir announced a global co‑development/co‑commercialization deal for prostate cancer candidate VIR‑5500 with $335M upfront/near‑term payments and up to $1.37B in milestones plus split U.S. economics — a major de‑risk and commercial validation for the program. Astellas and Vir Biotechnology Announce Global Strategic Collaboration
• Positive Sentiment: Encouraging Phase 1 VIR‑5500 data: Updated trial results show a favorable safety profile and meaningful activity (reported higher‑dose ORR of ~45%), underpinning the asset value and the Astellas deal. Vir Biotechnology Reports Positive Updated Phase 1 Results for VIR-5500
• Positive Sentiment: Quarterly beat and revenue acceleration: Q4 EPS beat estimates and revenue of $64.1M far exceeded expectations (~$19.9M), reflecting strong year‑over‑year growth and better near‑term commercial performance. Vir Biotechnology Q4 Earnings Highlights
• Positive Sentiment: Analyst upgrade/target increases: Needham raised its price target (to $18) and other firms reiterated/upgraded coverage, supporting upside expectations. PT Raised to $18 at Needham
• Neutral Sentiment: Broad media amplification: Extensive coverage (Forbes, Seeking Alpha, MSN) is increasing visibility and trading volume but does not change fundamentals by itself. What’s Happening With VIR Stock?
• Neutral Sentiment: Company disclosures: The earnings call transcript and slide deck provide added pipeline and cash‑position detail for investors to model future milestones and spend. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Proposed public offering: Vir filed to sell additional common stock — proceeds would strengthen the balance sheet but the offering is dilutive and can weigh on near‑term shares. Proposed Public Offering
• Negative Sentiment: Insider selling: Multiple insiders (including the CEO and several senior officers) reported stock sales on Feb. 23 — notable for sentiment and potential supply into the market. Insider Sales Report
• Negative Sentiment: Ongoing losses and wide negative margins: Despite revenue momentum and partnerships, Vir reported a sizable 2025 net loss and negative margins, making long‑term upside contingent on execution and milestone payments. 2025 Financial Results and Corporate Update

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.